On March 25, the OncoC4 ImmunoPharma "Large Molecule Drug Research and Development Center" was inaugurated in the Jiangning High-tech Zone of Nanjing. Party Secretary of Nanjing, Han Liming, met with Yang Liu, founder and chairman of OncoC4 ImmunoPharma, and his delegation.
Han Liming congratulated the opening of the research and development center and briefly introduced the development of the biopharmaceutical industry in Nanjing.
She said that accelerating the development of new and high-quality productive forces in line with local conditions is a significant requirement put forward by President Xi Jinping and a major task for Nanjing's high-quality development. The biopharmaceutical sector is a crucial area for the formation of new and high-quality productive forces. Nanjing boasts relatively rich educational and scientific resources, a solid industrial foundation, and certain early-mover advantages. She hopes that OncoC4 ImmunoPharma will fully leverage its innovation capabilities in areas such as immunotherapy, closely collaborate with related universities, research institutes, medical institutions, and enterprises in Nanjing, and accelerate the landing and conversion of innovative drugs. At the same time, she hopes that more enterprises and projects from the industrial chain ecosystem will be attracted to settle in Nanjing, achieving higher-level mutual benefits and win-win outcomes. Nanjing will continue to foster a favorable industrial innovation ecosystem, providing first-class environments and support for the growth and strengthening of enterprises.
Yang Liu expressed that Nanjing has abundant educational and talent resources, and the services provided to enterprises are practical and efficient. Since the project landed in Nanjing, progress has been smooth, boosting confidence in future development. OncoC4 ImmunoPharma will continue to increase its investment and layout in Nanjing, striving to play a greater role in strengthening the biopharmaceutical industry cluster in Nanjing.
The "Large Molecule Drug Research and Development Center" serves as OncoC4 ImmunoPharma's China R&D Center and future industrialization base, mainly responsible for the Phase III clinical trials of the next-generation anti-CTLA-4 monoclonal antibody innovative drug, among other tasks. In the future, it will be industrialized within the park.
Municipal leaders Jiang Yuejian and Lin Tao, along with OncoC4 ImmunoPharma founder Pan Zheng, also participated in the event.
Content source: Nanjing Daily/Zijinshan News reporter Zou Wei
